Suppression of Occurrence and Advancement of β‐Catenin‐accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase‐2 Inhibitor, Celecoxib

Yamada, Yasuhiro; Yoshimi, Naoki; Hirose, Yoshinobu; Hara, Akira; Shimizu, Masahito; Kuno, Toshiki; Katayama, Masaki; Zheng, Qiao; Mori, Hideki

doi:10.1111/j.1349-7006.2001.tb01139.x

Cited by 37 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, celecoxib reduced the number of ACF in Fischer F344 male rats by around 50%. Similar results were found by others [43]. At this concentration, celecoxib has also been shown to reduce the size and the number of tumours induced by AOM [23,44].…”

Section: Discussionsupporting

confidence: 87%

Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats

et al. 2003

View full text Add to dashboard Cite

-According to Burkitt's hypothesis, dietary fibres may protect against the development of colorectal cancer. In rats, studies have shown that only butyrate-producing fibres are protective. In parallel, in humans, non-steroidal anti-inflammatory drugs, which target cyclooxygenases, have been shown to display a protective effect against colorectal cancer. Among them, COX-2-selective inhibitors which present less side effects than non-selective agents, are promising as chemopreventive agents. Our aim was to analyse the effect of an association between butyrate-producing fibres and the COX-2 inhibitor on the development of aberrant crypt foci (ACF) in rats. Fisher F344 rats were fed with (1) a standard low fibre control diet; (2) the standard diet supplemented with 1500 ppm celecoxib; (3) a diet supplemented with 6% fructo-oligosaccharide (FOS); and (4) a diet with both celecoxib and FOS. Three weeks later, the rats were injected twice with azoxymethane and the number of ACF was determined 15 weeks later. In the control group, 43.8 ± 6.4 ACF were found. This number was not significantly modified by the addition of FOS or celecoxib alone to the diet. However, the association of FOS and celecoxib resulted in a 61% reduction in the number of ACF (P < 0.01). The number of aberrant crypt per foci was also reduced. Thus, although no significant effect of celecoxib or FOS alone was identified, the association of butyrate-producing fibre and celecoxib was effective in preventing the development of ACF. This preliminary study argues for a strong protective effect of such an association which deserves further studies. COX-2 / butyrate / colorectal cancer / NSAID

show abstract

Section: Discussionsupporting

confidence: 87%

Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats

et al. 2003

View full text Add to dashboard Cite

show abstract

“…ACFs are considered to be an early preneoplastic lesion in the colon (75), and the ability to decrease the frequency of ACF after carcinogen treatment is used routinely in experimental models of colon cancer to estimate the cancer preventive effect of different agents (76). It is particularly well established that NSAIDs (77)(78)(79) and celecoxib (80)(81)(82)(83) decrease the frequency of carcinogen-induced ACFs in the colon in animal models. It has also been shown that the number of ACF in patients who received sulindac sulfide is decreased (84).…”

Section: Discussionmentioning

confidence: 99%

Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa

Glebov

Rodríguez

Lynch³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…It is known that nonsteroidal anti-inflammatory drugs, and particularly celecoxib, decrease the frequency of ACF in humans as well as in rodent models of carcinogen-induced colon cancer (67)(68)(69)(70). We compared the changes in gene expression found in normal descending colonic mucosa of patients treated with celecoxib for 1 year (71) to the differences seen in gene expression between ACF and NM from the descending colon.…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa

Glebov

Rodríguez

Soballe

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Aberrant crypt foci (ACF) are considered the earliest identifiable preneoplastic colonic lesions; thus, a greater understanding of the nature of genetic changes underlying the transformation of normal colonic mucosa (NM) into ACF may provide insight into the mechanisms of carcinogenesis. ACF were identified by indigo carmine spraying onto colonic mucosa during colonoscopy and isolated as standard pinch biopsies of the mucosal areas containing the ACF. RNAs isolated from ACF and matched NM biopsies from the ascending and descending colons of 13 patients were analyzed on arrays containing 9128 cDNAs. Thirty-four differentially expressed (P < 0.001) genes were found in a paired comparison of the ACF and NM samples, and 25 of 26 matched pairs of ACF and NM could be correctly classified in leave-one-out cross-validation. Differential expression for seven of eight genes was confirmed by real-time reverse transcription-PCR. Furthermore, ACF and NM samples, including six pairs of ACF and NM samples that had not previously been analyzed by array hybridization, can be correctly classified on the basis of the overexpression in ACF of three selected genes (REG4, SRPN-B5, and TRIM29) evaluated by real-time reverse transcription-PCR. In a separate analysis of 13 biopsy pairs from either ascending or descending colon, ACF and NM samples could also be correctly classified by the gene expression patterns. Analysis of gene expression differences in ACF from the ascending and descending colon versus NM samples indicates that ACF from these distinct colonic locations are converging toward similar gene expression profiles and losing differences in gene expression characteristic of NM from the ascending versus descending colon. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2253 -62)

show abstract

Suppression of Occurrence and Advancement of β‐Catenin‐accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase‐2 Inhibitor, Celecoxib

Cited by 37 publications

References 23 publications

Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats

Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats

Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa

Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa

Contact Info

Product

Resources

About